FLT3 and leukemia: Xu et al. conducted a metanalysis of 15 randomized clinical trials and 15 retrospective trials to test the clinical benefit and safety of GO in different leukemia subgroups, confirming the survival advantage in favorable and intermediate cytogenetics, but also in NPM1 mutated and in FLT3-wt AMLs and in patients aged < 70 years [104].